A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
A phase 2 trial of YL201 in prostate cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.
Overview
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC is a phase 2 interventional study registered as NCT06241846 by MediLink Therapeutics (Suzhou) Co., Ltd., with 100 participants planned, started 2024-02-22 and due to reach its primary completion in 2027-02. Interventions recorded: YL201 for Injection. Conditions listed: Metastatic Castration-resistant Prostate Cancer (mCRPC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）
Shares YL201, MediLink Therapeutics.
- TrialA Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)
Shares YL201, MediLink Therapeutics.
- TrialA Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer
Shares YL201, MediLink Therapeutics.
- TrialA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Shares YL201, MediLink Therapeutics.
- TrialA Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
Shares YL201, MediLink Therapeutics.
- TargetB7-H3
Shares YL201, MediLink Therapeutics, Prostate cancer.